Engineering Commons^™

Scalable Nano Particle Production Of Low Bioavailability Pharmaceuticals For Augmented Aqueous Solubility, Aaron Madden

HIM 1990-2015

The billion dollar pharmaceutical research and development pipeline suffers greatly from high attrition rates of novel therapeutic compounds within pre-clinical and clinical trials. Poor bioavailability in many new drugs, originating in the various methodologies of high throughput screening, may explain part of these growing failure rates. One interpretation of this phenomenon relies on bioavailability's correlation with aqueous solubility; much modern processing allows chemicals to fully develop without touching water, yielding upwards of 90% of new chemical entities practically insoluble in aqueous media. Thus, one approach to alleviating bioavailability and potentially clinical attrition rates necessitates augmented aqueous solubility. The amorphous nanoparticle …